iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the best medical device stocks to invest in right now. Truist cut the price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $170 from $200 on April 15, reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm telling investors in the research note that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated that the stock should trade at least in line with, if not higher than, its peer group average, given the upward bias to consensus revenue growth forecasts into the out- years as well as the company’s re-accelerating revenue growth potential in 2027, which could materialize upon MCT, Mobile Cardiac Telemetry service, approval.
iRhythm Technologies, Inc. (NASDAQ:IRTC) also received a rating update from BTIG on April 13. The firm cut the price target on the stock to $185 from $215 and maintained a Buy rating on the shares. The rating update came as part of a broader research name on Medical Technology.
iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital healthcare company that provides design, development, and commercialization of device-based technology. It provides ambulatory cardiac monitoring services, along with solutions to detect, predict, and prevent disease.
While we acknowledge the potential of IRTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
